Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Hoth Therapeutics, Inc. - Common Stock (NQ:HOTH)

0.7918 +0.0203 (+2.63%)
Streaming Delayed Price Updated: 3:23 PM EDT, Apr 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Hoth Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Why Entrada Therapeutics Shares Are Trading Lower By 32%; Here Are 31 Stocks Moving Premarket
Gainers IceCure Medical Ltd (NASDAQ: ICCM) shares rose 158% to $2.42 in pre-market trading after the company announced interim results from the ICESECRET study for the treatment of patients with small... 
Via Benzinga
Why Is Hoth Therapeutics (HOTH) Stock Up 24% Today?
Hoth Therapeutics (HOTH) stock is rising higher on Monday with heavy trading and positive results from a Phase 1 clinical trial of BioLexa. 
Via InvestorPlace
Why Global Payments Shares Are Trading Lower By Around 8%? Here Are 41 Stocks Moving In Monday's Mid-Day Session
Gainers 1847 Holdings LLC (NASDAQ: EFSH) shares surged 72.7% to $3.25 after the company reported it sees over $60 million in revenue and over $7 million in cash flow from operations in 2023 from its... 
Via Benzinga
Hoth Therapeutics Shares Surge On Encouraging Preclinical Data From Alzheimer's Program
Via Benzinga
Hoth Therapeutics Adds New Pipeline Program For Stroke, Brain Injury
Via Benzinga
Nasdaq Down Over 100 Points; Chicago PMI Drops Further
U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping more than 100 points on Monday. 
Via Benzinga
Hoth Therapeutics (NASDAQ: HOTH) Releases BioLexa Phase 1B Trial Results Showing Positive Results in Treating Mild to Moderate Atopic Dermatitis
Hoth Therapeutics, Inc. (NASDAQ: HOTH) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and development 
Via Spotlight Growth
Hoth Therapeutics' Atopic Dermatitis Candidate Shows Improvement In Severity, Shares Jump
Hoth Therapeutics Inc (NASDAQ: HOTH) announced Phase 1b trial data for BioLexa in adult patients with mild-to-moderate atopic dermatitis. 
Via Benzinga
What's Going On With Hoth Therapeutics Stock?
Hoth Therapeutics Inc (NASDAQ: HOTH) shares are trading higher Monday after the company announced positive BioLexa Phase 1b clinical trial results. 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 53 companies reached new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  During Friday, 125 stocks hit new 52-week lows. 
Via Benzinga
Why Fulgent Genetics Shares Are Trading Higher Today
Via Benzinga
Why Taysha Gene Therapies Shares Jumped Over 97%; Here Are 70 Biggest Movers From Yesterday
Gainers Taysha Gene Therapies, Inc. (NASDAQ: TSHA) surged 97.4% to close at $2.98 after Astellas Pharma Inc announced it will invest a total of $50 million to acquire 15% of the company. 
Via Benzinga
Nasdaq Surges Over 200 Points; General Electric Posts Downbeat Earnings
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 200 points on Tuesday. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 120 companies set new 52-week lows. 
Via Benzinga
Why Crown Holdings Shares Are Trading Lower By Around 22%? Here Are 46 Stocks Moving In Tuesday's Mid-Day Session
Gainers 
Via Benzinga
S&P 500 Rises Over 1%; General Motors Earnings Top Views
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 1.8% on Tuesday. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
We're starting off the day with an overview of the biggest pre-market stock movers on Tuesday and the latest news this morning! 
Via InvestorPlace
Why Qualtrics International Shares Are Trading Sharply Higher; Here Are 23 Stocks Moving Premarket
Gainers Taysha Gene Therapies, Inc. (NASDAQ: TSHA) rose 43% to $2.16 in pre-market trading. Astellas Pharma Inc. announced plans to invest a total of $50 million to acquire 15% of Taysha Gene... 
Via Benzinga
Why Hoth Therapeutics Shares Are Falling In Monday's After-Hours Session
Hoth Therapeutics Inc (NASDAQ: HOTH) shares are trading lower by 11.12% to $0.29 during Monday's after-hours session after the company  
Via Benzinga
Hoth Therapeutics And 3 Other Stocks Under $3 Insiders Are Aggressively Buying
The Dow Jones jumped by around 197 points on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around... 
Via Benzinga
The Daily Biotech Pulse: AstraZeneca's COVID-19 Vaccine As Effective As mRNA Shots, Humanigen's Lenzilumab Disappoints In COVID-19 Study, Positive Preclinical Data From Hoth's Alzheimer's Program
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
U.S. Stocks Turn Higher; PepsiCo Posts Upbeat Q2 Results
U.S. stocks turned higher midway through trading after recording losses in the previous session. 
Via Benzinga
Why Is Canoo Surging By 80%? 52 Stocks Moving In Tuesday's Mid-Day Session
Gainers 
Via Benzinga
Why Hoth Therapeutics Shares Are Skyrocketing Today
Hoth Therapeutics Inc (NASDAQ: HOTH) shares are trading higher by 17% to $0.47 Tuesday morning after the company announced its HT-ALZ therapeutic showed cognitive improvements in an Alzheimer's Disease... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Redhill Biopharma (NASDAQ:RDHL) stock moved upwards by 16.4% to $0.89 during Friday's pre-market session. The market value of their outstanding shares is at $47.6 million. As per the press... 
Via Benzinga
Recap of Tuesday's Biotech Catalysts - End of the Day Summary
Ionis (NASDAQ: IONS) announced that Eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid... 
Via Benzinga
InvestorNewsBreaks – Hoth Therapeutics Inc. (NASDAQ: HOTH) Shares Pricing of $7M Public Offering
Via Investor Brand Network
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers 
Via Benzinga
The Daily Biotech Pulse: Aeglea Stock Jumps On Inherited Metabolic Disease Data, Partial Hold Lifted On Gilead's 2 Blood Trials, Early Data From Novartis' KRAS Inhibitor And More
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.